Outlook: Clinical data package continues to build
Clinical data from CALM, STORM and CANON trials presented at scientificconferences further highlight the potential efficacy of CAVATAK (oncolytic
virus) against a range of cancers using several delivery approaches. While
the evidence of CAVATAK’s efficacy as a single agent continues to build, it
is also likely to be attractive to big pharma companies seeking
complementary therapies to boost immune responses to their checkpoint
inhibitors; a Phase Ib trial in combination with ipilimumab (Yervoy) is
already underway. We value Viralytics at A$189m or A$1.03 per share.
Viralytics is engaged in advancing the clinical and preclinical development of its product CAVATAK™. Co. is actively progressing with development of CAVATAK across a range of cancers within targeted clinical trials.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.